Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
Age of cancer incidence; Multistage progression; History of theories; Progression dynamics; Theory I; Theory II; Genetics of progression; Carcinogens; Aging; Inheritance; Stem cells : tissue renewal; Stem cells : population genetics; Cell lineage history
c.1 BC Cancer Agency VAN Library | Available |
Table of Contents:; Chapter 1 Introduction -- Chapter 2 Pelvis and abdomen -- Chapter 3 Thorax -- Chapter 4 Head and neck (Extracranial) -- Chapter 5 Intracranial -- Chapter 6 CT in Radiotherapy -- Answers to self-test questions -- Structure key
Table of Contents:; Anatomy of writing -- Finding, refining, and defining a topic -- How to select and query a publication -- Finding and documenting sources -- Organizing the article -- Writing effectively -- All about tables, figures, graphs, illustrations, and photos -- Submissions and revisions…
Table of Contents:; Risk Assessment for Breast Cancer -- Genetic Evaluation for Women at Increased Risk -- Imaging Screening and Surveillance -- Risk-Reducing Surgery for BRCA1/2 Genetic Mutation Carriers -- Prophylactic Oophorectomy for Patients with Germline BRCA Mutations -- Pathology of BRCA Tu…
c.1 BC Cancer Agency VAN Library | Available |
Contents:; Genetic Testing, Some Themes and Some Basics -- Autosomal Dominant Inheriance and Huntington Disease -- Autosomal Recessive Inheritance and Cystic Fibrosis -- X-linked Inheritance: a Question of Gender -- Genetics Testing in Cancer -- DNA Testing, Genes and Identity -- Out of Sequence: G…
c.1 BC Cancer Agency VAN Library | Available |
"Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia…
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2-9 June 2015